Reinhardt, Dirk 1965-
Dirk Reinhardt researcher (ORCID 0000-0001-6300-3434)
VIAF ID: 50421156 ( Personal )
Permalink: http://viaf.org/viaf/50421156
Preferred Forms
4xx's: Alternate Name Forms (3)
5xx's: Related Names (11)
- 551 _ _ ‡a Essen ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _ ‡a Georg-August-Universität Göttingen ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Göttingen, Univ
- 551 _ _ ‡a Hannover ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _ ‡a Klinik für Pädiatrische Hämatologie und Onkologie ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Klinik für Pädiatrische Hämatologie und Onkologie
- 510 2 _ ‡a Medizinische Hochschule Hannover
- 510 2 _ ‡a Medizinische Hochschule Hannover ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 551 _ _ ‡a Neumünster ‡4 ortg ‡4 https://d-nb.info/standards/elementset/gnd#placeOfBirth
- 510 2 _ ‡a Universität Duisburg-Essen ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Universitätsklinikum Essen ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
Efficient small extracellular vesicles (EV) isolation method and evaluation of EV-associated DNA role in cell–cell communication in cancer | |
Einfluss von Interferon-Beta, Interferon-Gamma, Interleukin-1Beta, Interleukin-3, GM-CSF und Erythropoetin auf die Hämoglobinsynthese in venösem Blut in vitro | |
Entscheidungsfindung am Lebensende in der Pädiatrischen Onkologie und Intensivmedizin | |
Gold nanoparticles for genetic therapy of hemophilia B | |
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS | |
Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML | |
A study of regulatory challenges of paediatric oncology phase I/II trial submissions and guidance on protocol development |